Preli Pharmaceutical's Carfilzomib for Injection (60mg) Approved for Listing in China

K-LinePoet · 2026-03-17T00:34:19+00:00

Puli Pharmaceuticals recently received the drug registration approval from the National Medical Products Administration (NMPA) for Carfilzomib for Injection (60mg) (registration category: Chemical Drugs, Category 4). This approval is considered to be equivalent to passing the consistency evaluation of quality and efficacy for generic drugs, and the product has been officially approved for market launch. It is a potent anti-tumor medication used to treat relapsed or refractory multiple myeloma.

K-LinePoet

2026-03-17 00:34:19

Puli Pharmaceutical recently received the drug registration approval from the National Medical Products Administration (NMPA) for Carfilzomib for Injection (60mg) (Registration Category: Chemical Drugs Class 4), which is considered to have passed the consistency evaluation of quality and efficacy for generic drugs and has been officially approved for market. This product is a potent anti-tumor medication for the treatment of relapsed/refractory multiple myeloma.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes